Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
CAPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.68 - $23.40
Previous CloseN/A
Volume187.65K
Average Volume (3M)1.34M
Market Cap
$324.13M
Enterprise Value$335.51M
Total Cash (Recent Filing)$122.80M
Total Debt (Recent Filing)$4.42M
Price to Earnings (P/E)―
Beta2.46
Next Earnings
Nov 12, 2025EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding45,716,976
10 Day Avg. Volume1,507,613
30 Day Avg. Volume1,336,862
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue25.05
Enterprise Value/Gross Profit27.39
Enterprise Value/Ebitda-4.76
Forecast
1Y Price Target
$21.22Price Target Upside199.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyDeramiocel shows a real effect on cardiac tissue, with 21 out of 22 cardiac parameters favoring its use, indicating potential benefits for cardiac function.
Financial StabilityCapricor maintains a strong cash balance sheet, which supports its ongoing development and regulatory efforts.
Regulatory ProgressRegulatory alignment between Capricor and the FDA positions deramiocel favorably for BLA resubmission.
Bears Say
Clinical ChallengesThe HOPE-2 study failed to demonstrate efficacy in a prespecified 12-month change in the mid-level (elbow) dimension of the PUL 1.2 metric according to the FDA.
FDA ConcernsAlthough the FDA cited a lack of consistency in secondary and exploratory cardiac-related endpoints, 21 out of 22 cardiac parameters favored deramiocel, suggesting a real effect on cardiac tissue.
Capricor Therapeutics News
CAPR FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was $5.68 and its highest was $23.40 in the past 12 months.
What is Capricor Therapeutics’s market cap?
Capricor Therapeutics’s market cap is $324.13M.
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 45 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.476 by -$0.094.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -0.54.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 45,716,976 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.476. Following the earnings report the stock price went up 2.813%.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Currently, no hedge funds are holding shares in CAPR
Capricor Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.22 (199.29% Upside)
$21.22 (199.29% Upside)
Blogger Sentiment
Bullish
CAPR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.02%
12-Months-Change
Fundamentals
Return on Equity
-120.15%
Trailing 12-Months
Asset Growth
248.95%
Trailing 12-Months
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
CAPR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted Capricor Therapeutics' strong cash position and progress in its exosome program but faced significant challenges with the FDA's complete response letter, increased expenses, and zero revenue, resulting in a net loss. The regulatory delays and lack of clarity on the approval path for Deramiocel contributed to a negative outlook.View all CAPR earnings summariesCAPR Stock 12 Month Forecast
Average Price Target
$21.22
▲(199.29% Upside)
Technical Analysis
Ownership Overview
16.79% Insiders
7.26% Mutual Funds
15.34% Other Institutional Investors
51.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---